review Open AccessTop 1% cited
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
American Journal of Transplantation · 2006 · Vol. 6(5) · pp. 859–866
Mark D. Pescovitz✉(Indiana University – Purdue University Indianapolis)
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies ResearchMedicineRituximabImmunologyThrombocytopenic purpuraRheumatoid arthritisCD20Lymphoproliferative disordersLymphomaMyasthenia gravisImmune system
MeSH terms
RituximabAntibodies, MonoclonalArthritis, RheumatoidB-LymphocytesHumansImmunologic FactorsLymphocyte DepletionMyasthenia GravisTransplantation ImmunologyPurpura, Thrombocytopenic, IdiopathicAntigens, CD20Antibodies, Monoclonal, Murine-Derived
Funding
- National Institutes of Health
- Genentech
Citations
611
FWCI
19.39
field-weighted impact
References
83
Percentile
100%
vs. same field & year
Citations per year
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Cells · 2020 · 887 citations
References
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Blood · 1994 · 1,936 citations
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Journal of Clinical Oncology · 1998 · 2,755 citations
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Lara D. Veeken · 2001 · 517 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.